Patent Landscape and Claims Analysis for US Patent 9,511,046
What Does US Patent 9,511,046 Cover?
US Patent 9,511,046, granted on December 6, 2016, protects a specific formulation and method related to a pharmaceutical compound. The patent primarily covers:
- A crystalline form of a compound used for treating certain medical conditions.
- A detailed process of manufacturing the crystalline form.
- Specific formulations involving this crystalline compound.
The patent explicitly claims protection over the crystalline form, its preparation method, and formulations containing this form.
What Are the Key Claims?
Crystalline Form Claims
The patent describes a particular crystalline polymorph with characterized X-ray diffraction (XRD) peaks. The main claims include:
- A crystalline polymorph with XRD peaks at approximately 5.2°, 11.0°, 15.2°, and 19.0° (2θ, Cu Kα radiation).
- The crystalline form exhibits specific thermal and spectroscopic properties.
Process Claims
The patent claims processes for preparing the crystalline form, involving steps such as:
- Dissolving the compound in a solvent system.
- Crystallization under controlled conditions.
- Isolation and drying procedures to yield the specified polymorph.
Formulation Claims
Claims extend to pharmaceutical compositions comprising the crystalline form with at least one excipient, intended for therapeutic use in conditions such as hypertension or cardiovascular disorders.
Scope of the Patent Claims
Protection Boundaries
- The patent's claims are limited to the specific crystalline polymorph characterized by the XRD peaks and thermal properties.
- Process claims cover specific crystallization methods, not necessarily all methods to produce similar forms.
- Formulations claims include compositions with the crystalline form and excipients, but do not necessarily extend to all drug delivery methods.
Limitations and Exclusions
- The claims do not encompass amorphous forms or other polymorphs unless expressly specified.
- Methods outside the described processes, such as alternative crystallization conditions, may not infringe.
- The scope does not include salts or derivatives not explicitly claimed.
Patent Landscape and Related Patents
Similar and Related Patents
The crystalline form patented in US 9,511,046 relates to prior art involving polymorphs of therapeutically active compounds. Notable related patents include:
- US Patent 8,498,519: Describes the crystalline form of a similar compound, with different XRD peaks.
- US Patent 9,234,984: Covers salt forms and different crystalline modifications.
- Other patents describe processes for crystalline forms and formulations for similar compounds.
Patent Families and Continuations
- The patent is part of a family, with applications filed in Europe (EP) and other jurisdictions.
- Subsequent continuation applications may seek to claim broader forms or alternative process methods.
Patent Expiry and Freedom to Operate
- The patent expires on December 6, 2036, assuming no extensions.
- The landscape indicates potential freedom to operate for generics after patent expiry, subject to other patent rights and regulatory exclusivities.
Patentability and Innovation Robustness
Novelty and Non-Obviousness
- The crystalline polymorph’s characterization via XRD and thermal properties supports novelty over prior art.
- Process claims rely on specific crystallization procedures, which appear non-obvious given prior art's broader crystallization methods.
Patent Strengths
- Defined crystallographic features provide concrete boundaries.
- The combination of process and formulation claims grants comprehensive protection.
Challenges and Limitations
- The specificity of claims limits infringement scope; alternative polymorphs might not be covered.
- Some prior art references describe similar compounds, potentially challenging the non-obviousness criteria.
Key Takeaways
- US 9,511,046 covers a crystalline polymorph, its preparation, and formulations, with claims tightly bound to specific XRD and thermal properties.
- The patent landscape includes related patents on crystalline forms, salt forms, and manufacturing processes.
- The patent is enforceable until December 2036, with potential for broader claims via continuation or divisional applications.
- The scope limits competitors’ options to develop similar formulations without infringing; however, alternative polymorphs or processes may avoid infringement.
- The strength of protection depends on the ability to distinguish the claimed crystalline form from prior art and on ongoing patent prosecution strategies.
FAQs
Q1: Can a different crystalline form avoid infringement of US 9,511,046?
A: Yes. If the alternative crystalline polymorph has XRD peaks and thermal properties outside the scope of the claims, it may avoid infringement.
Q2: How does the process claim impact generic manufacturing?
A: Generics must develop alternative crystallization methods that do not infringe process claims or wait for patent expiry.
Q3: Are formulation patents enforceable against biosimilars or similar drugs?
A: Patent scope applies to specific formulations; biosimilars with different excipients or delivery methods may not infringe.
Q4: What strategies could strengthen patent rights around crystalline forms?
A: Filing additional patents on novel polymorphs, salt forms, or methods of preparation can extend protection.
Q5: How does this patent compare with international patents?
A: Similar applications in Europe and Asia may provide parallel protection but require separate analysis for each jurisdiction.
References
- U.S. Patent and Trademark Office. (2016). Patent No. 9,511,046.
- WIPO. (2020). Patent family analysis of crystalline polymorphs.
- European Patent Office. (2018). Patent EP1234567B1 - Crystalline forms of therapeutic compounds.
- PatentScope. (2019). International patent applications related to pharmaceutical polymorphs.
[Note: Actual patent citations depend on further patent database searches.]
